Product Description
Details
NOVEMBER 2019 EDITION
Antimicrobial resistance (AMR) is creating new kinds of infections and “superbugs” that are resistant to current antibiotic medicines. New drugs and technologies are under development to stop these superbugs. These pharmaceutical technologies have the potential to displace existing antibiotics. We have identified the 6 key large pathogen opportunities in this space and developed market forecasts out to 2024. We have looked at the technology picture too, giving you plain language understanding of the different ways pathogens and infections can be diagnosed. We profile 100 companies, large and small, working in this area.
Forecasts are provided to 2024 and are broken out by country, pathogen and five different technology opportunities. Additional breakout data relevant to your own area of interest is available upon request, and free of charge with the corporate license.
Make investment decisions and market valuations with confidence using the latest data.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School
Additional Information
Additional Information
| Publisher name | Howe Sound Research |
|---|---|
| Format | |
| Page count | 327 |
| Publication date | 5 Nov 2019 |
| Table of contents |
|
